Balchem Corporation

Análisis de la acción Balchem Corporation (BCPC)

$170.730

+0.205 (+0.12%)Al cierre

Loading chart…
Máximo
172.390
Apertura
171.160
Precio medio ponderado por volumen
171.02
Volumen
197.30K
Capitalización
4.92B
Mínimo
169.950
Importe
33.74M
EV/EBITDA, TTM
18.63

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

balchem.com

Análisis de IA of Balchem Corporation (BCPC)

Comprar

Balchem Corp is a good buy right now due to its strong financial performance, with a current price of $170.73 and a forward P/E ratio of 29.33, indicating reasonable valuation relative to growth expectations. The company reported a 11.2% year-over-year revenue growth in Q2 2026, reaching $284 million, which exceeded expectations. However, the main risk is the high RSI of 72.67, indicating that the stock may be overbought in the short term.

Métricas de valoración

El PER previsto actual de Balchem Corporation (BCPC) es 29.33, frente a su media de 5 años de 32.65.

PER previsto

Valor razonable
Media 5A P/E
32.65
P/E actual
29.33
Sobrevalorada
36.01
Infravalorada
29.30

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
20.55
EV/EBITDA actual
18.63
Sobrevalorada
22.64
Infravalorada
18.46

Precio/ventas previsto

Valor razonable
Media 5A P/S
4.78
P/S actual
4.55
Sobrevalorada
5.36
Infravalorada
4.20

Escenarios de precio de Alphio AI para BCPC

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%BCPC

$162.17

Precio del escenario

B

Base

Base · 50%BCPC

$159.96

Precio del escenario

B

Bajista

Bajista · 25%BCPC

$150.29

Precio del escenario

Ballenas con BCPC en cartera

S

Salem Investment Counselors, Inc.

+ Con en carteraBCPC

+4.26%

Rentabilidad a 3 meses

W

Wasatch Advisors LP

+ Con en carteraBCPC

-0.86%

Rentabilidad a 3 meses

N

Nationwide Fund Advisors

+ Con en carteraBCPC

-1.49%

Rentabilidad a 3 meses

Cronología de eventos

2026-07-31 (ET)

07:31:00

Balchem Reports Q2 Revenue of $284M

2026-04-30 (ET)

07:50:00

Balchem Q1 Revenue $270.71M Beats Consensus

2026-03-09 (ET)

08:20:00

Balchem Launches Metalosate T.E.A.M. Plant Tissue Analysis Platform

2026-02-20 (ET)

07:20:00

Balchem Reports Q4 Revenue of $263.6M

2025-12-22 (ET)

08:10:00

Eastman and Balchem Welcome EU's Anti-Dumping Duties on Choline Chloride Imports from China

Noticias

Preguntas frecuentes sobre BCPC, respondidas por Alphio AI

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. It operates in the Basic Materials sector (CHEMICALS & ALLIED PRODUCTS industry).

Balchem Corp is a good buy right now due to its strong financial performance, with a current price of $170.73 and a forward P/E ratio of 29.33, indicating reasonable valuation relative to growth expectations. The company reported a 11.2% year-over-year revenue growth in Q2 2026, reaching $284 million, which exceeded expectations. However, the main risk is the high RSI of 72.67, indicating that the stock may be overbought in the short term.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar